A phase I study of binimetinib (MEK 162), a MEK inhibitor, plus carboplatin and pemetrexed chemotherapy in non-squamous non-small cell lung cancer
Andrea S. Fung, Donna M. Graham, Eric X. Chen, Tracy Stockley, Tong Zhang, Lisa W. Le, Hamzeh Albaba, Katherine M.W. Pisters, Penelope A. Bradbury, Martina Trinkaus, Matthew Chan, Saroosh Arif, Urszula Zurawska, J. Rothenstein, Dianne Zawisza, Saiful Effendi, S. Gill, M. Sawczak, J. Law, Natasha B. Leighl
Topics & Concepts
MedicinePemetrexedCarboplatinKRASInternal medicineOncologyMEK inhibitorLung cancerNeuroblastoma RAS viral oncogene homologAdverse effectRashTrametinibChemotherapyCancerColorectal cancerMAPK/ERK pathwayKinaseCisplatinCell biologyBiologyLung Cancer Treatments and MutationsMelanoma and MAPK PathwaysLung Cancer Diagnosis and Treatment